Mathieu Pioche, MD, a gastroenterologist at Hôpital Edouard Herriot in Lyon, France, and lead author of the study, and colleagues evaluated consecutive patients who underwent endoscopic resections for esophageal, gastric, duodenal or colonic superficial lesions at two university hospitals in France. In each case, the gel was applied with a catheter immediately after resection.
Here are five points:
1. Researchers assessed a total of 42 lesions, averaging 17.1 mm in 37 patients: eight lesions in the esophagus, 10 in the stomach, eight in the duodenum, three ampullary and 13 colorectal tumors.
2. Twenty-eight of the lesions were resected in high-risk situations.
3. Researchers reported no difficulties during application, nor any adverse events related to the gel.
4. Four cases of delayed bleeding (9.5 percent) occurred despite the application of PuraStat.
5. Three cases required endoscopic hemostasis.
More articles on GI & endoscopy:
Stay ahead of the quality-reporting game: Leverage data to maximize outcomes & reimbursement
Boston Scientific launches AXIOS Stent, EndoGastric Solutions presents promising 3-year TIF data — 6 GI company key notes
El Camino Hospital launches 1st GutCheck System trial: 4 points
